×
Remdesivir Now Approved for COVID Outpatients, Too
https://www.medpagetoday.com/infectiousdisease/covid19/96812

Jan 22nd, 2022 - Intravenous antiviral remdesivir (Veklury) is now approved for treating COVID patients in an outpatient setting, providing another therapeutic option during the Omicron surge, the FDA announced late on Friday. Already approved in the hospital setting, the agency expanded remdesivir's indication to include individuals ages 12 and up (who weigh 40 kg or more) with mild to moderate COVID-19 who ar...

FDA Takes Actions to Expand Use of Treatment for Outpatients with Mild-to-Moderate COVID-19 | FDA
https://www.fda.gov/news-events/press-announcements/fda-takes-actions-expand-use-treatment-outpatients-mild-moderate-covid-19

Jan 21st, 2022 - For Immediate Release: January 21, 2022 Today, the U.S. Food and Drug Administration took two actions to expand the use of the antiviral drug Veklury (remdesivir) to certain non-hospitalized adults and pediatric patients for the treatment of mild-to-moderate COVID-19 disease. This provides another treatment option to reduce the risk of hospitalization in high-risk patients. Previously, the use ...

Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomi...
https://doi.org/10.1503/cmaj.211698
CMAJ : Canadian Medical Association Journal = Journal De ... Ali K, Azher T et. al.

Jan 21st, 2022 - The role of remdesivir in the treatment of patients in hospital with COVID-19 remains ill defined in a global context. The World Health Organization Solidarity randomized controlled trial (RCT) evaluated remdesivir in patients across many countries, with Canada enrolling patients using an expanded data collection format in the Canadian Treatments for COVID-19 (CATCO) trial. We report on the Can...

Pro-Vax Fla. Official Put on Leave; Blood Sample Tube Shortage; 1M Superbug Deaths
https://www.medpagetoday.com/infectiousdisease/covid19/96763

Jan 20th, 2022 - Note that some links may require registration or subscription. A top Florida health official was placed on leave after encouraging his colleagues to get vaccinated against COVID-19. (Washington Post) NIAID Director Anthony Fauci, MD, suggested that Pfizer's COVID-19 vaccine could be authorized for kids under 5 as soon as next month. (Fortune) Due to the Omicron variant, updated NIH COVID guidel...

Remdesivir significantly reduces SARS-CoV-2 viral load on nasopharyngeal swabs in hospi...
https://doi.org/10.1002/jmv.27598
Journal of Medical Virology; Biancofiore A, Mirijello A et. al.

Jan 20th, 2022 - Remdesivir is a broad-spectrum antiviral agent able to inhibit the RNA polymerase of SARS-CoV-2. At present, studies focusing on the effect of remdesivir on viral load (VL) are few and with contrasting results. Aim of the present study was to evaluate the effect of remdesivir on SARS-CoV-2 VL from nasopharyngeal swabs (cycle threshold criterion) in a sample of patients treated with the drug, co...

The anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesviruses Reactivation through...
https://doi.org/10.1128/aac.02395-21
Antimicrobial Agents and Chemotherapy; Chen J, Dai L et. al.

Jan 19th, 2022 - Recently, Remdesivir and Molnupiravir were approved for treating COVID-19 caused by SARS-CoV-2 infection. However, little is known about the impact of these drugs on other viruses pre-existed in COVID-19 patients. Here we report that Remdesivir but not Molnupiravir induced lytic reactivation of KSHV and EBV, two major oncogenic herpesviruses. Remdesivir induced mature virion production from lat...

Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massi...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8755559
Antiviral Research; Focosi D, Maggi F et. al.

Jan 17th, 2022 - Massive usage of antiviral compounds during a pandemic creates an ideal ground for emergence of resistant strains. Remdesivir, a broad-spectrum inhibitor of the viral RNA-dependent RNA polymerase (RdRp), was extensively prescribed under emergency use authorization during the first 18 months of the COVID19 pandemic, before randomized controlled trials showed poor efficacy in hospitalized patient...

Subcutaneous remdesivir administration prevents interstitial pneumonia in rhesus macaqu...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8755413
Antiviral Research; Williamson BN, Pérez-Pérez L et. al.

Jan 16th, 2022 - The utility of remdesivir treatment in COVID-19 patients is currently limited by the necessity to administer this antiviral intravenously, which has generally limited its use to hospitalized patients. Here, we tested a novel, subcutaneous formulation of remdesivir in the rhesus macaque model of SARS-CoV-2 infection that was previously used to establish the efficacy of remdesivir against this vi...

Efficacy of the use of mefenamic acid combined with standard medical care vs. standard ...
https://doi.org/10.3892/ijmm.2022.5084
International Journal of Molecular Medicine; Guzman-Esquivel J, Galvan-Salazar HR et. al.

Jan 15th, 2022 - Mefenamic acid is a non‑steroidal anti‑inflammatory drug exhibiting a wide range of anti‑inflammatory, antipyretic, analgesic and probable antiviral activities. The present study evaluated the efficacy of treatment with mefenamic acid combined with standard medical care vs. standard medical care plus a placebo in ambulatory patients with coronavirus disease 2019 (COVID‑19; nasal/oropharyngeal s...

Coronavirus Disease 2019 (COVID-19) Treatment & Management
https://emedicine.medscape.com/article/2500114-treatment

Jan 14th, 2022 - Approach Considerations Utilization of programs established by the FDA to allow clinicians to gain access to investigational therapies during the pandemic has been essential. The expanded access (EA) and emergency use authorization (EUA) programs allowed for rapid deployment of potential therapies for investigation and investigational therapies with emerging evidence. A review by Rizk et al des...

COVID-19 Treatment: Investigational Drugs and Other Therapies
https://emedicine.medscape.com/article/2500116-print

Jan 14th, 2022 - Coronavirus disease 2019 (COVID-19) is defined as illness caused by a novel coronavirus now called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; formerly called 2019-nCoV), which was first identified amid an outbreak of respiratory illness cases in Wuhan City, Hubei Province, China.[1] It was initially reported to the WHO on December 31, 2019. On January 30, 2020, the WHO declare...

A Description of COVID-19-Directed Therapy in Children Admitted to US Intensive Care Un...
https://doi.org/10.1093/jpids/piab123
Journal of the Pediatric Infectious Diseases Society; Schuster JE, Halasa NB et. al.

Jan 14th, 2022 - It is unclear how acute coronavirus disease 2019 (COVID-19)-directed therapies are used in children with life-threatening COVID-19 in US hospitals. We described characteristics of children hospitalized in the intensive care unit or step-down unit (ICU/SDU) who received COVID-19-directed therapies and the specific therapies administered. Between March 15, 2020 and December 27, 2020, children <18...

Inpatient COVID-19 mortality has reduced over time: Results from an observational cohort.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8757902
PloS One; Bechman K, Yates M et. al.

Jan 14th, 2022 - The Covid-19 pandemic in the United Kingdom has seen two waves; the first starting in March 2020 and the second in late October 2020. It is not known whether outcomes for those admitted with severe Covid were different in the first and second waves. The study population comprised all patients admitted to a 1,500-bed London Hospital Trust between March 2020 and March 2021, who tested positive fo...

COVID-19 Treatment: Investigational Drugs and Other Therapies
https://emedicine.medscape.com/article/2500116-overview

Jan 14th, 2022 - Overview Coronavirus disease 2019 (COVID-19) is defined as illness caused by a novel coronavirus now called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; formerly called 2019-nCoV), which was first identified amid an outbreak of respiratory illness cases in Wuhan City, Hubei Province, China. [1] It was initially reported to the WHO on December 31, 2019. On January 30, 2020, the W...

COVID-19 Treatment: Investigational Drugs and Other Therapies
http://emedicine.medscape.com/article/2500116-overview

Jan 14th, 2022 - Overview Coronavirus disease 2019 (COVID-19) is defined as illness caused by a novel coronavirus now called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; formerly called 2019-nCoV), which was first identified amid an outbreak of respiratory illness cases in Wuhan City, Hubei Province, China. [1] It was initially reported to the WHO on December 31, 2019. On January 30, 2020, the W...

Which COVID Outpatient Therapy Should Clinicians Reach For?
https://www.medpagetoday.com/infectiousdisease/covid19/96655

Jan 13th, 2022 - Due to the Omicron variant and the short supply of COVID therapeutics, NIH recommends certain therapies over others for patients at high risk of progressing to severe COVID, said federal officials on a call with clinicians Wednesday. In order of preference, clinicians should use the oral antiviral nirmatrelvir-ritonavir (Paxlovid), the monoclonal antibody sotrovimab, the IV antiviral remdesivir...

Remdesivir and dexamethasone as tools to relieve hospital care systems stressed by COVI...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754316
PloS One; Béraud G, Timsit JF et. al.

Jan 13th, 2022 - Remdesivir and dexamethasone are the only drugs providing reductions in the lengths of hospital stays for COVID-19 patients. We assessed the impacts of remdesivir on hospital-bed resources and budgets affected by the COVID-19 outbreak. A stochastic agent-based model was combined with epidemiological data available on the COVID-19 outbreak in France and data from two randomized control trials. S...

Human airway lineages derived from pluripotent stem cells reveal the epithelial respons...
https://doi.org/10.1152/ajplung.00397.2021
American Journal of Physiology. Lung Cellular and Molecul... Wang R, Hume AJ et. al.

Jan 13th, 2022 - There is an urgent need to understand how SARS-CoV-2 infects the airway epithelium and in a subset of individuals leads to severe illness or death. Induced pluripotent stem cells (iPSCs) provide a near limitless supply of human cells that can be differentiated into cell types of interest, including airway epithelium, for disease modeling. We present a human iPSC-derived airway epithelial platfo...

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8654464
Drug Resistance Updates : Reviews and Commentaries in Ant... Drożdżal S, Rosik J et. al.

Jan 8th, 2022 - The COVID-19 pandemic is one of the greatest threats to human health in the 21st century with more than 257 million cases and over 5.17 million deaths reported worldwide (as of November 23, 2021. Various agents were initially proclaimed to be effective against SARS-CoV-2, the etiological agent of COVID-19. Hydroxychloroquine, lopinavir/ritonavir, and ribavirin are all examples of therapeutic ag...

COVID-19 presenting as acute epiglottitis: A case report and literature review.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683275
Auris, Nasus, Larynx; Iwamoto S, Sato MP et. al.

Jan 7th, 2022 - Coronavirus disease 2019 (COVID-19) occasionally causes acute laryngitis, requiring emergency treatment. Understanding the characteristic laryngeal findings can help diagnose COVID-19 earlier, prevent worsening infection, and properly manage airway obstruction. Herein, we report the case of a 44-year-old male with acute epiglottitis likely caused by COVID-19. On presentation, chest computed tom...